Sep 07, 2021
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
NEEDHAM, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment for its pivotal phase 3 study of
Additional Formats
Jul 26, 2021
Candel Therapeutics Announces Pricing of Initial Public Offering
NEEDHAM, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public
Additional Formats
May 27, 2021
Candel Therapeutics to present at upcoming Jefferies Virtual Healthcare Conference
NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Executive Officer, will present an overview of the Company at the upcoming Jefferies
Additional Formats
May 11, 2021
Candel Therapeutics names Carrie S. Cox as Chairman of its Board of Directors
NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Carrie S. Cox has been named Chairman of the Board of Directors, effective immediately. Paul Manning, the outgoing Chairman, will
Additional Formats
Displaying 1 - 10 of 13